LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Udayachalerm, Sariya"
  2. AU="Tambaro, Federica"

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis.

    Tariot, Pierre N / Boada, Mercè / Lanctôt, Krista L / Hahn-Pedersen, Julie / Dabbous, Firas / Udayachalerm, Sariya / Raket, Lars Lau / Halchenko, Yuliya / Michalak, Wojciech / Weidner, Wendy / Cummings, Jeffrey

    Alzheimer's research & therapy

    2024  Volume 16, Issue 1, Page(s) 36

    Abstract: Background: Understanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments. We examined associations among ...

    Abstract Background: Understanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments. We examined associations among changes in Alzheimer's disease (AD) stages and outcomes that are important to patients and their care partners including activities of daily living (ADLs), geriatric depression, neuropsychiatric features, cognitive impairment, and the probabilities of being transitioned to a long-term care facility (i.e., institutionalization). We also estimated the total time spent at each stage and annual transition probabilities in AD.
    Methods: The study included participants with unimpaired cognition, mild cognitive impairment (MCI) due to AD, and mild, moderate, and severe AD dementia in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) database. The associations among change in AD stages and change in relevant outcomes were estimated using linear mixed models with random intercepts. The probability of transitioning to long-term care facilities was modeled using generalized estimating equations. The total length of time spent at AD stages and annual transition probabilities were estimated with multistate Markov models.
    Results: The estimated average time spent in each stage was 3.2 years in MCI due to AD and 2.2, 2.0, and 2.8 years for mild, moderate, and severe AD dementia, respectively. The annual probabilities of progressing from MCI to mild, moderate, and severe AD dementia were 20, 4, and 0.7%, respectively. The incremental change to the next stage of participants with unimpaired cognition, MCI, and mild, moderate, and severe AD dementia (to death) was 3.2, 20, 26.6, 31, and 25.3%, respectively. Changes in ADLs, neuropsychiatric features, and cognitive measures were greatest among participants who transitioned from MCI and mild AD dementia to more advanced stages. Participants with MCI and mild and moderate AD dementia had increasing odds of being transitioned to long-term care facilities over time during the follow-up period.
    Conclusions: The findings demonstrated that participants with early stages AD (MCI or mild dementia) were associated with the largest changes in clinical scale scores. Early detection, diagnosis, and intervention by disease-modifying therapies are required for delaying AD progression. Additionally, estimates of transition probabilities can inform future studies and health economic modeling.
    MeSH term(s) Humans ; Aged ; Activities of Daily Living ; Disease Progression ; Alzheimer Disease/drug therapy ; Dementia/diagnosis ; Cognitive Dysfunction/psychology ; Mental Status and Dementia Tests ; Probability
    Language English
    Publishing date 2024-02-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 2506521-X
    ISSN 1758-9193 ; 1758-9193
    ISSN (online) 1758-9193
    ISSN 1758-9193
    DOI 10.1186/s13195-024-01399-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Association between clinical dementia rating and clinical outcomes in Alzheimer's disease.

    Lanctôt, Krista L / Boada, Mercè / Tariot, Pierre N / Dabbous, Firas / Hahn-Pedersen, Julie / Udayachalerm, Sariya / Raket, Lars Lau / Saiontz-Martinez, Cynthia / Michalak, Wojciech / Weidner, Wendy / Cummings, Jeffrey

    Alzheimer's & dementia (Amsterdam, Netherlands)

    2024  Volume 16, Issue 1, Page(s) e12522

    Abstract: Introduction: We examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI-Q]), and cognitive impairment in Alzheimer' ...

    Abstract Introduction: We examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI-Q]), and cognitive impairment in Alzheimer's disease (AD).
    Methods: We used data from the National Alzheimer's Coordinating Center Uniform Data Set and defined cognitively unimpaired and AD stages using CDR-global.
    Results: Functional and neuropsychiatric symptoms occur as early as the mild cognitive impairment (MCI) phase. The adjusted lest square mean FAS (95% confidence interval [CI]) was lowest in cognitively unimpaired (3.88 [3.66, 4.11] to 5.01 [4.76, 5.26]) and higher with more advanced AD (MCI: 8.17 [6.92, 9.43] to 20.87 [19.53, 22.20]; mild: 18.54 [17.57, 19.50] to 28.13 [27.14, 29.12]; moderate: 26.01 [25.31, 26.70] to 29.42 [28.73, 30.10]). FAS and NPI-Q scores increased steeply with MCI (NPI-Q: 5.55 [4.89, 6.20] to 7.11 [6.43, 7.78]) and mild AD dementia (NPI-Q: 6.66 [5.72, 7.60] to 8.32 [7.32, 9.33]).
    Discussion: CDR-global staged AD by capturing differences in relevant outcomes along AD progression.
    Highlights: There were strong associations among CDR and the various outcomes relevant to healthcare providers, patients, and their care givers, such as activities of daily living.Overall, activities of daily living, neuropsychiatric symptoms, and cognitive function outcomes deteriorated over time and can be observed in early stages of AD (MCI or mild dementia).Our findings directly inform the current understanding of AD progression and can aid in care planning and benefit assessments of early AD interventions to delay the progression of AD to more advanced stages.
    Language English
    Publishing date 2024-01-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2832898-X
    ISSN 2352-8729
    ISSN 2352-8729
    DOI 10.1002/dad2.12522
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence.

    Udayachalerm, Sariya / Renouard, Maranda G / Anothaisintawee, Thunyarat / Thakkinstian, Ammarin / Veettil, Sajesh K / Chaiyakunapruk, Nathorn

    Journal of medical economics

    2021  Volume 25, Issue 1, Page(s) 26–37

    Abstract: Objectives: To perform a systematic review and meta-analysis to pool the incremental net benefit (INB) of each herpes zoster vaccine [i.e. Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV)].: Methods: We initially identified individual ... ...

    Abstract Objectives: To perform a systematic review and meta-analysis to pool the incremental net benefit (INB) of each herpes zoster vaccine [i.e. Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV)].
    Methods: We initially identified individual studies by hand-searching reference lists of the relevant systematic review articles. An updated comprehensive search was performed in Medline, Scopus, and Embase until June 2020 for additional studies. Studies were eligible if they assessed the cost-effectiveness/utility of any pair among ZVL and RZV, and no vaccine and reported economic outcomes. Details of the study characteristics, economic model inputs, costs, and outcomes were extracted. INB was calculated with monetary units adjusting for purchasing power parity for 2019 US dollars and pooled by meta-analysis.
    Results: A total of 37 studies were pooled for meta-analysis stratified by perspectives [i.e. societal (SP) and third-party payer (TPP)] and vaccine types. In SP, ZVL was cost-effective compared to no vaccine when vaccinated at ages of 50-59 and 70-79 years with INBs (95% CI) of $0.61 (0.37, 0.85) and $9.67 (5.20, 14.14), respectively. RZV was cost-effective for those aged 60-69 and 70-79 years with INBs of $75.61 (17.98, 133.23) and $85.01 (30.02, 140.01), respectively. In TPP, ZVL was cost-effective compared to no vaccine when vaccinated at age 70-79 years with INB of $7.57 (0.27, 14.86) and RZV was cost-effective at 60-69 years with INB $220.87 (47.80, 393.93). The cost-effectiveness of RZV was robust across a series of sensitivity analyses, but ZVL differs on different vaccination ages.
    Conclusions: RZV may be cost-effective for vaccination in ages of 60-79 years for both SP and TPP perspectives, while ZVL might be cost-effective in some age groups, but results are not robust.
    MeSH term(s) Aged ; Cost-Benefit Analysis ; Herpes Zoster/prevention & control ; Herpes Zoster Vaccine ; Humans ; Middle Aged ; Vaccination ; Vaccines, Synthetic
    Chemical Substances Herpes Zoster Vaccine ; Vaccines, Synthetic
    Language English
    Publishing date 2021-11-15
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2270945-9
    ISSN 1941-837X ; 1369-6998
    ISSN (online) 1941-837X
    ISSN 1369-6998
    DOI 10.1080/13696998.2021.2008195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Opioid prescribing and health outcomes in opioid-naive patients: Analysis of a statewide health information exchange.

    Udayachalerm, Sariya / Bair, Matthew J / Illingworth Plake, Kimberly S / Huang, Chien-Yu / Murray, Michael D / Foster, David R

    Journal of the American Pharmacists Association : JAPhA

    2021  Volume 61, Issue 5, Page(s) 623–631.e3

    Abstract: Background: Widespread use of prescription opioids is associated with adverse outcomes.: Objective: To identify factors associated with adverse health outcomes and health care use using a statewide health information exchange.: Methods: This is a ... ...

    Abstract Background: Widespread use of prescription opioids is associated with adverse outcomes.
    Objective: To identify factors associated with adverse health outcomes and health care use using a statewide health information exchange.
    Methods: This is a retrospective cohort study using the Indiana Network for Patient Care. Adult opioid-naive patients who received an opioid prescription between January 2012 and December 2017 were included. The outcomes included (1) a composite outcome of any combination of opioid abuse, dependence, or overdose, (2) all-cause mortality, and (3) health care use. Independent variables included opioid dosage, dispensed amount, days supply, concurrent use of short-acting (SA) and long-acting (LA) opioids, and concurrent use with benzodiazepine or gabapentinoids. Additional variables included patients' age, sex, race, modified Charlson Comorbidity Index score, mental health conditions, and medications for opioid use disorders. Factors associated with composite outcome and mortality were identified using Cox proportional hazards and reported as adjusted hazard ratio (aHR) and 95% CI. Factors associated with health care use were identified using Poisson regression and reported as adjusted incidence rate ratio (aIRR) and 95% CI.
    Results: 1,328,287 opioid prescriptions were identified for 341,722 patients. Opioid-related factors associated with the composite outcome, mortality, and hospitalizations, respectively, included opioid dosage (aHR 1.003 [95% CI 1.001-1.006]; aHR not applicable; aIRR 1.07 [1.06-1.08]), opioid days supply (aHR 1.03 [1.02-1.03]; aHR 1.009 [1.005-1.014]; aIRR 0.94 [0.92-0.96]), concurrent SA/LA opioids (aHR 2.12 [1.78-2.54]; aHR 1.40 [1.14-1.70]; aIRR 1.40 [1.37-1.42]), and use of benzodiazepines/gabapentinoids (aHR 1.68 [1.38-2.04]; aHR 1.23 [1.01-1.51]; aIRR 1.25 [1.23-1.27]).
    Conclusion: Many factors are associated with poor health outcomes, especially concurrent use of SA and LA opioids and overlapping prescriptions of opioids with benzodiazepines or gabapentinoids. Identification of factors associated with adverse outcomes may help identify patients at risk for poor outcomes and could inform possible interventions.
    MeSH term(s) Adult ; Analgesics, Opioid/adverse effects ; Benzodiazepines/adverse effects ; Health Information Exchange ; Humans ; Outcome Assessment, Health Care ; Practice Patterns, Physicians' ; Retrospective Studies
    Chemical Substances Analgesics, Opioid ; Benzodiazepines (12794-10-4)
    Language English
    Publishing date 2021-05-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2118585-2
    ISSN 1544-3450 ; 1544-3191 ; 1086-5802
    ISSN (online) 1544-3450
    ISSN 1544-3191 ; 1086-5802
    DOI 10.1016/j.japh.2021.04.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis.

    Udayachalerm, Sariya / Rattanasiri, Sasivimol / Angkananard, Teeranan / Attia, John / Sansanayudh, Nakarin / Thakkinstian, Ammarin

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

    2018  Volume 24, Issue 9_suppl, Page(s) 117S–126S

    Abstract: New oral anticoagulants (NOACs; ie, direct thrombin inhibitor [DTI] and factor Xa [FXa] inhibitors) were used as alternatives to warfarin. Specific antidotes (idarucizumab for dabigatran and andexanet alfa for FXa inhibitors) and hemostatic reversal ... ...

    Abstract New oral anticoagulants (NOACs; ie, direct thrombin inhibitor [DTI] and factor Xa [FXa] inhibitors) were used as alternatives to warfarin. Specific antidotes (idarucizumab for dabigatran and andexanet alfa for FXa inhibitors) and hemostatic reversal agents were used for lowering bleeding, but their efficacies were still uncertain. The objectives of this study were to estimate and compare the efficacy of NOAC antidotes on bleeding reversal and death. Studies were identified from MEDLINE and Scopus databases until May 2018. Case reports/series and cohorts were selected if they assessed reversal or death rates. Data were independently extracted by 2 reviewers. Individual patient data and aggregated data of outcomes were extracted from case reports/series and cohorts. Binary regression was used to estimate outcome rates, risk ratio (RR) along with 95% confidence interval (CI). Interventions were NOACs and reversal agents (ie, DTI-specific, DTI-standard, FXa-specific, and FXa-standard). Among 220 patients of 93 case reports/series, reversal rates were 95.9%, 77.6%, and 71.5% for DTI-specific, FXa-standard, and DTI-standard. Pooled RRs for DTI-specific and FXa-standard versus DTI-standard, respectively, were 1.34 (CI: 1.13-1.60) and 1.09 (CI: 0.84-1.40). Death rate was 0.18 (CI: 0.06-0.57) times lower in DTI-specific versus DTI-standard. For pooling 10 subcohorts, pooled RRs were 1.08 (CI: 1.00-1.16), 1.29 (CI: 1.20-1.39), and 1.13 (CI: 1.01-1.25) for DTI-specific, FXa-specific, and FXa-standard versus DTI-standard. In conclusion, specific reversal agents might be useful for reversal of bleeding and lowering the risk of death than standard reversal agents. Our findings were based on case reports/series and selected cohorts, further comparative studies are thus needed.
    MeSH term(s) Administration, Oral ; Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Hemorrhage/blood ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Humans
    Chemical Substances Anticoagulants
    Language English
    Publishing date 2018-09-03
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 1237357-6
    ISSN 1938-2723 ; 1076-0296
    ISSN (online) 1938-2723
    ISSN 1076-0296
    DOI 10.1177/1076029618796339
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Meta-Analysis of

    Khaeso, Kanyarat / Udayachalerm, Sariya / Komvilaisak, Patcharee / Chainansamit, Su-On / Suwannaying, Kunanya / Laoaroon, Napat / Kuwatjanakul, Pitchayanan / Nakkam, Nontaya / Sukasem, Chonlaphat / Puangpetch, Apichaya / Tassaneeyakul, Wichittra / Chaiyakunapruk, Nathorn

    Frontiers in pharmacology

    2021  Volume 12, Page(s) 784712

    Abstract: Backgound: ...

    Abstract Backgound:
    Language English
    Publishing date 2021-12-02
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2021.784712
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top